论文部分内容阅读
豚鼠离体心脏灌流造成心肌钙反常模型,以丹参酮Ⅱ_A磺酸钠(DS-201)为保护剂,测定心肌组织蛋白释放和钙摄取量,观察作用效果。并与已知钙拮抗剂异搏定比较,探讨DS-201的钙拮抗作用。实验结果表明,DS-201对心肌钙反常损伤具有明显的保护作用,抑制钙内流,减轻钙反常过程中心肌组织钙沉积和心肌损伤所致的蛋白(酶)释放(P<0.01)。该作用在一定范围内具有剂量依赖关系。30mg/L、40mg/LDS-201分别能降低心肌组织蛋白释放量52.8%、66.2%,降低钙摄取量25.8%、36.9%。作用效果优于异搏定,后者降低蛋白释放量47.5%,降低钙摄取量23.9%。
Cardiac calcium anomalies were induced by isolated cardiac perfusion in guinea pigs. The protein and calcium uptake of myocardium was determined by using sodium tanshinone Ⅱ-A sulfonate (DS-201) as protective agent. And compared with known calcium antagonist verapamil, to explore the calcium antagonism of DS-201. The experimental results show that DS-201 has a significant protective effect on myocardial calcium abnormality, inhibits influx of calcium, and relieves the release of protein (enzyme) due to calcium deposition and myocardial injury in the process of calcium abnormality (P <0.01). This effect is dose-dependent within a certain range. 30mg / L, 40mg / LDS-201 can reduce myocardial tissue protein release 52.8%, 66.2%, reduce calcium uptake 25.8%, 36.9%. The effect is better than verapamil, the latter reduces protein release 47.5%, reduce calcium intake 23.9%.